# PRD Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prd-therapeutics

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.prdtherapeutics.com
- Total disclosed funding: $8.9M
- Latest round: Series A (Sep 1, 2023)
- Investors on record: 5

## About

Based in Tokyo, Japan, and founded in 2021, PRD Therapeutics, Inc., a.k.a. PRD Therapeutics, researches and develops new lipid metabolism regulators that are effective for rare diseases that cause lipid metabolism abnormalities. In September 2023, PRD Therapeutics, Inc. raised JPY 1.3 billion in a Series A funding from JAFCO Group, JIC Venture Growth Investments, Mizuho Capital, and SMBC Venture Capital, with participation from Taiho Innovations, LLC. As of September 2023, Renji Hosoda is the CEO of the company.

The company’s product line includes PRD001, an oral lipid-lowering drug for HoFH, which is a rare dyslipidemia with few treatments. PRD001 uses a new mechanism to regulate the blood cholesterol levels of patients.

PRD Therapeutics plans to use its proceeds from September 2023 funding to conduct clinical trials for PRD001, a lead compound derived from a fungus that can help treat lipid metabolism problems.

## Funding rounds

- Series A, Sep 1, 2023, $8.9M — JAFCO Group, SMBC Venture Capital, Mizuho Capital, JIC Venture Growth Investments, Taiho Innovations, LLC.

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series A
- Taiho Innovations, LLC. — Series A